VOLUNTARY ANNOUNCEMENT FINANCE LEASE AGREEMENT

ANNOUNCEMENT (1) UNUSUAL MOVEMENT IN TRADING VOLUME AND (2) DENOSUMAB (60MG) APPROVED FOR MARKETING IN BOLIVIA

Boan's Denosumab (60mg) Approved for Market Launch in Bolivia

Boan Biotech announced that its self-developed Denosumab Injection 60mg (BA6101) has officially received approval for market from the Bolivian National Agency of Medicines and Health Technologies (Age...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025

Boan Biotech Grants NKF Exclusive Rights to Commercialize Two Denosumab Drugs in the US

Yantai, Shandong, December 9 – Boan Biotech announced a licensing agreement with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), granting NKF the exclusive rights to commercializ...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025

Boan Biotech’s Boyoujing^® Approved for Marketing in China for the Treatment of nAMD and DME

Boan Biotech today announced that its aflibercept intravitreous injection Boyoujing® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of neovascular...

VOLUNTARY ANNOUNCEMENT BOYOUJING (AFLIBERCEPT INTRAVITREOUS INJECTION) APPROVED FOR MARKETING IN CHINA

Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK

Yantai, China, October 7, 2025 – Boan Biotech today announced that the Marketing Authorization Applications (MAAs) for its two denosumab injections, BA6101, a 60 mg denosumab injection for ortho...

VOLUNTARY ANNOUNCEMENT MARKETING AUTHORISATION APPLICATIONS FOR THE COMPANY'S TWO DENOSUMAB INJECTIONS ACCEPTED IN THE UK